Ligand Gaussian Accelerated Molecular Dynamics 2 (LiGaMD2): Improved Calculations of Ligand Binding Thermodynamics and Kinetics with Closed Protein Pocket
- PMID: 36706316
- PMCID: PMC10316156
- DOI: 10.1021/acs.jctc.2c01194
Ligand Gaussian Accelerated Molecular Dynamics 2 (LiGaMD2): Improved Calculations of Ligand Binding Thermodynamics and Kinetics with Closed Protein Pocket
Abstract
Ligand binding thermodynamics and kinetics are critical parameters for drug design. However, it has proven challenging to efficiently predict ligand binding thermodynamics and kinetics from molecular simulations due to limited simulation timescales. Protein dynamics, especially in the ligand binding pocket, often plays an important role in ligand binding. Based on our previously developed Ligand Gaussian accelerated molecular dynamics (LiGaMD), here we present LiGaMD2 in which a selective boost potential was applied to both the ligand and protein residues in the binding pocket to improve sampling of ligand binding and dissociation. To validate the performance of LiGaMD2, the T4 lysozyme (T4L) mutants with open and closed pockets bound by different ligands were chosen as model systems. LiGaMD2 could efficiently capture repetitive ligand dissociation and binding within microsecond simulations of all T4L systems. The obtained ligand binding kinetic rates and free energies agreed well with available experimental values and previous modeling results. Therefore, LiGaMD2 provides an improved approach to sample opening of closed protein pockets for ligand dissociation and binding, thereby allowing for efficient calculations of ligand binding thermodynamics and kinetics.
Figures




References
-
- Hauser AS; Attwood MM; Rask-Andersen M; Schiöth HB; Gloriam DE, Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery 2017, 16 (12), 829–842; - PMC - PubMed
- Miura K, An overview of current methods to confirm protein-protein interactions. Protein and peptide letters 2018, 25 (8), 728–733; - PMC - PubMed
- Renaud J-P; Chari A; Ciferri C; Liu W.-t.; Rémigy H-W; Stark H; Wiesmann C, Cryo-EM in drug discovery: achievements, limitations and prospects. Nature Reviews Drug Discovery 2018, 17 (7), 471–492. - PubMed
-
- Schuetz DA; de Witte WEA; Wong YC; Knasmueller B; Richter L; Kokh DB; Sadiq SK; Bosma R; Nederpelt I; Heitman LH; Segala E; Amaral M; Guo D; Andres D; Georgi V; Stoddart LA; Hill S; Cooke RM; De Graaf C; Leurs R; Frech M; Wade RC; de Lange ECM; IJzerman AP; Muller-Fahrnow A; Ecker GF, Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discov Today 2017, 22 (6), 896–911; - PubMed
- Tonge PJ, Drug-Target Kinetics in Drug Discovery. ACS chemical neuroscience 2018, 9 (1), 29–39; - PMC - PubMed
- Ahmad K; Rizzi A; Capelli R; Mandelli D; Lyu W; Carloni P, Enhanced-Sampling Simulations for the Estimation of Ligand Binding Kinetics: Current Status and Perspective. Frontiers in Molecular Biosciences 2022, 9; - PMC - PubMed
- Ijzerman AP; Guo D, Drug - Target Association Kinetics in Drug Discovery. Trends in Biochemical Sciences 2019, 44 (10), 861–871; - PubMed
- Tonge PJ, Drug–Target Kinetics in Drug Discovery. ACS Chemical Neuroscience 2018, 9 (1), 29–39; - PMC - PubMed
- Ferruz N; De Fabritiis G, Binding Kinetics in Drug Discovery. Molecular Informatics 2016, 35 (6–7), 216–226; - PubMed
- Zhou Y; Fu Y; Yin W; Li J; Wang W; Bai F; Xu S; Gong Q; Peng T; Hong Y; Zhang D; Zhang D; Liu Q; Xu Y; Xu HE; Zhang H; Jiang H; Liu H, Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate. Journal of Medicinal Chemistry 2021, 64 (4), 1844–1855. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources